ClinicalTrials.gg
RecruitingNCT06085053Updated Dec 5, 2023

A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects

A Phase 1 interventional study of TQA3038 injection and TQA3038 injection matching placebo in Chronic Hepatitis b, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited — 4 open to participants now, 6 under way, 1 of them phase 3. Hepatitis B, Chronic · Sino Biopharmaceutical Limited.

Planned enrollment
10th of 13
54 · median 116
Started
2023
with 1 other
Phase 1
2 of 13
1 open now
Registered
6th of 13
by date

Among the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, this one is the 10th largest by planned enrollment, is one of 2 that started in 2023, is one of 2 in phase 1, and was the 6th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

4 of the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is a phase 1 study in which healthy adult subjects will receive TQA3038 or placebo and will be assessed for safety, tolerability, pharmacokinetics.

In the single ascending dose (SAD) part, healthy adult subjects will receive one dose of TQA3038 or placebo, administered subcutaneously (SC).

03

Conditions studied

  • Chronic Hepatitis b

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age 18~60 years.
  • (BMI) 19 - 26 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Any chronic or acute medical condition that makes the volunteer unsuitable for participation;
  • History or evidence of drug or alcohol abuse;
  • History of intolerance to SC injection;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    TQA3038 injection

    One dose of TQA3038 injection in Day 1.

    Drug: TQA3038 injection

  • Placebo comparator
    TQA3038 injection matching placebo

    One dose of TQA3038 injection matching placebo in Day 1.

    Drug: TQA3038 injection matching placebo

Interventions

  • DrugTQA3038 injection

    TQA3038 is an injection.

  • DrugTQA3038 injection matching placebo

    Placebo injection contains no active substance.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: Up to 85 days.

  2. Number of subjects with clinically significant abnormalities

    Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v5.0.

    Time frame: Up to 85 days.

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Maximum concentration of TQA3038 and its metabolite in plasma

    Time frame: Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose

  2. Time to Reach Maximum Plasma Concentration (Tmax)

    Time to reach Cmax of TQA3038 and its metabolite in plasma

    Time frame: Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose

  3. Area Under the Plasma Concentration Versus Time Curve (AUC)

    Area under the curve of TQA3038 and its metabolite from time 0 to last measurable time

    Time frame: Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose

  4. Apparent Terminal Elimination Half-life (T1/2)

    Apparent Elimination Half-life (T1/2) of TQA3038 in Plasma

    Time frame: Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose

  5. Apparent Plasma Clearance (CL/F)

    Apparent Plasma Clearance (CL/F) of TQA3038 in Plasma

    Time frame: Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose

  6. Fraction eliminated in the urine

    Apparent Plasma Clearance (CL/F) of TQA3038 in Plasma

    Time frame: Predose, 0-4 hours, 4-8 hours, 8-12 hours, 12-24 hours, 48 hours and 168 hours after dose on Day 1.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2024, 13 months after the start.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 13 months is below that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2023
First posted
Oct 16, 2023
StartActual
Nov 30, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2025
Last update
Dec 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06085053
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Nov 30, 2023
Primary completion
Dec 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Dec 5, 2023

Study contacts

Dong Liu, Doctor
Contact
ld_2069@163.com
+86 13507183749
ZheLong Liu, Doctor
Contact
liuzhelong@163.com
+86 13986235028

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion